This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Aaron L, Franco OE, Hayward SW. Review of prostate anatomy and embryology and the etiology of benign prostatic hyperplasia. Urol Clin North Am. 2016; 43: 279–288.AaronLFrancoOEHaywardSWReview of prostate anatomy and embryology and the etiology of benign prostatic hyperplasia201643279288Search in Google Scholar
Toivanen R, Shen MM. Prostate organogenesis: tissue induction, hormonal regulation and cell type specification. Development. 2017; 144: 1382–1398.ToivanenRShenMMProstate organogenesis: tissue induction, hormonal regulation and cell type specification201714413821398Search in Google Scholar
Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim-Biophys Acta. 2010; 1803: 55–71.BrewKNagaseHThe tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity201018035571Search in Google Scholar
Winer A, Adams S, Mignatti P. Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Mol Cancer Ther. 2018; 17: 1147–1155.WinerAAdamsSMignattiPMatrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes20181711471155Search in Google Scholar
Wiśniowski T, Bryda J, Kurzepa J, Wątroba S. The role of matrix metalloproteinases in pathogenesis of human bladder cancer. Acta Biochim Pol. 2021; 68: 547–555.WiśniowskiTBrydaJKurzepaJWątrobaSThe role of matrix metalloproteinases in pathogenesis of human bladder cancer202168547555Search in Google Scholar
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer. J Clin. 2016; 66: 7–30.SiegelRLMillerKDJemalACancer statistics201666730Search in Google Scholar
Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG, de Bono JS. Prostate cancer. Lancet. 2016; 387: 70–82.AttardGParkerCEelesRASchröderFTomlinsSATannockIDrakeCGde BonoJSProstate cancer20163877082Search in Google Scholar
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: 359–386.FerlayJSoerjomataramIDikshitREserSMathersCRebeloMParkinDMFormanDBrayFCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 20122015136359386Search in Google Scholar
Białkowska K, Marciniak W, Muszyńska M, Baszuk P, Gupta S, Jaworska-Bieniek K, Sukiennicki G, Durda K, Gromowski T, Prajzendanc K, et al. Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population. PLoS One. 2018; 13: e0201065.BiałkowskaKMarciniakWMuszyńskaMBaszukPGuptaSJaworska-BieniekKSukiennickiGDurdaKGromowskiTPrajzendancKAssociation of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population201813e0201065Search in Google Scholar
Bell KJ, Del Mar C, Wright G, Dickinson J, Glasziou P. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer. 2015; 137: 1749–1757.BellKJDel MarCWrightGDickinsonJGlasziouPPrevalence of incidental prostate cancer: A systematic review of autopsy studies201513717491757Search in Google Scholar
Pikala M, Burzyńska M, Maniecka-Bryła I. Epidemiology of mortality due to prostate cancer in Poland, 2000–2015. Int J Environ Res Public Health. 2019; 16: 2881.PikalaMBurzyńskaMManiecka-BryłaIEpidemiology of mortality due to prostate cancer in Poland, 2000–20152019162881Search in Google Scholar
Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006; 11: 1388–1413.HsingAWChokkalingamAPProstate cancer epidemiology20061113881413Search in Google Scholar
Dulińska-Litewka J, Hałubiec P, Łazarczyk A, Szafrański O, Sharoni Y, McCubrey JA, Gąsiorkiewicz B, Bohn T. Recent progress in discovering the role of carotenoids and metabolites in prostatic physiology and pathology—A review—part II: carotenoids in the human studies. Antioxidants. 2021; 10: 319.Dulińska-LitewkaJHałubiecPŁazarczykASzafrańskiOSharoniYMcCubreyJAGąsiorkiewiczBBohnTRecent progress in discovering the role of carotenoids and metabolites in prostatic physiology and pathology—A review—part II: carotenoids in the human studies202110319Search in Google Scholar
Dulińska-Litewka J, Sharoni Y, Hałubiec P, Łazarczyk A, Szafrański O, McCubrey JA, Gąsiorkiewicz B, Laidler P, Bohn T. Recent progress in discovering the role of carotenoids and their metabolites in Prostatic physiology and pathology with a focus on prostate cancer—A review—part I: Molecular mechanisms of carotenoid action. Antioxidants. 2021; 10: 585.Dulińska-LitewkaJSharoniYHałubiecPŁazarczykASzafrańskiOMcCubreyJAGąsiorkiewiczBLaidlerPBohnTRecent progress in discovering the role of carotenoids and their metabolites in Prostatic physiology and pathology with a focus on prostate cancer—A review—part I: Molecular mechanisms of carotenoid action202110585Search in Google Scholar
Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, Tempany CM, Choyke PL, Cornud F, Margolis DJ, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol. 2019; 76: 340–351.TurkbeyBRosenkrantzABHaiderMAPadhaniARVilleirsGMacuraKJTempanyCMChoykePLCornudFMargolisDJProstate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2201976340351Search in Google Scholar
Bhavsar A, Verma S. Anatomic imaging of the prostate. Biomed Res Int. 2014; 2014: 728539.BhavsarAVermaSAnatomic imaging of the prostate20142014728539Search in Google Scholar
Van der Kwast T, Bubendorf L, Mazerolles C, Raspollini MR, Van Leenders GJ, Pihl CG, Kujala P. Pathology Committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Virchows Arch. 2013; 463: 367–377.Van der KwastTBubendorfLMazerollesCRaspolliniMRVan LeendersGJPihlCGKujalaPPathology Committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC)2013463367377Search in Google Scholar
D’Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999; 17: 168–172.D’AmicoAVWhittingtonRMalkowiczSBFonduruliaJChenMHKaplanIBeardCJTomaszewskiJERenshawAAWeinAPretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer199917168172Search in Google Scholar
Rodrigues G, Warde P, Pickles T, Crook J, Brundage M, Souhami L, Lukka H. Genitourinary radiation oncologists of canada. Pre-treatment risk stratification of prostate cancer patients: A critical review. Can Urol Assoc J. 2012; 6: 121–127.RodriguesGWardePPicklesTCrookJBrundageMSouhamiLLukkaHGenitourinary radiation oncologists of canada. Pre-treatment risk stratification of prostate cancer patients: A critical review20126121127Search in Google Scholar
Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994; 151: 1283–1290.CatalonaWJRichieJPAhmannFRHudsonMAScardinoPTFlaniganRCDeKernionJBRatliffTLKavoussiLRDalkinBLComparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men199415112831290Search in Google Scholar
Loeb S, Catalona WJ. The prostate health index: a new test for the detection of prostate cancer. Ther Adv Urol. 2014; 6: 74–77.LoebSCatalonaWJThe prostate health index: a new test for the detection of prostate cancer201467477Search in Google Scholar
Nordström T, Vickers A, Assel M, Lilja H, Grönberg H, Eklund M. Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur Urol. 2015; 68: 139–146.NordströmTVickersAAsselMLiljaHGrönbergHEklundMComparison between the four-kallikrein panel and prostate health index for predicting prostate cancer201568139146Search in Google Scholar
Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008; 179: 1587–1592.DerasILAubinSMBlaseADayJRKooSPartinAWEllisWJMarksLSFradetYRittenhouseHPCA3: a molecular urine assay for predicting prostate biopsy outcome200817915871592Search in Google Scholar
Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol. 2016; 70: 740–748.Van NesteLHendriksRJDijkstraSTrooskensGCornelEBJanninkSAde JongHHesselsDSmitFPMelchersWJDetection of high-grade prostate cancer using a urinary molecular biomarker-based risk score201670740748Search in Google Scholar
Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, Rieger-Christ K, Jones JS, Magi-Galluzzi C, Mangold LA, et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol. 2014; 192: 1081–1087.PartinAWVan NesteLKleinEAMarksLSGeeJRTroyerDARieger-ChristKJonesJSMagi-GalluzziCMangoldLAClinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies201419210811087Search in Google Scholar
Wątroba S, Wiśniowski T, Bryda J, Kurzepa J. Characteristics of matrix metalloproteinases and their role in embryogenesis of the mammalian respiratory system. PostepyHig Med Dosw. 2021; 75: 24–34.WątrobaSWiśniowskiTBrydaJKurzepaJCharacteristics of matrix metalloproteinases and their role in embryogenesis of the mammalian respiratory system2021752434Search in Google Scholar
Wątroba S, Kocot J, Bryda J, Kurzepa J. Serum activity of MMP-2 and MMP-9 and stromielisin-1 concentration as predictors in the pathogenesis of bronchopulmonary dysplasia in preterm neonates. PostepyHig Med Dosw. 2019; 73: 703–712.WątrobaSKocotJBrydaJKurzepaJSerum activity of MMP-2 and MMP-9 and stromielisin-1 concentration as predictors in the pathogenesis of bronchopulmonary dysplasia in preterm neonates201973703712Search in Google Scholar
Ries C. Cytokine functions of TIMP-1. Cell Mol Life Sci. 2014; 71: 659–672.RiesCCytokine functions of TIMP-1201471659672Search in Google Scholar
Woolley DE, Roberts DR, Evanson JM. Inhibition of human collagenase activity by a small molecular weight serum protein. Biochem-Biophys Res Commun. 1975; 66: 747–754.WoolleyDERobertsDREvansonJMInhibition of human collagenase activity by a small molecular weight serum protein197566747754Search in Google Scholar
Murphy G, Houbrechts A, Cockett MI, Williamson RA, O’Shea M, Docherty AJ. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry. 1991; 30: 8097–8102.MurphyGHoubrechtsACockettMIWilliamsonRAO’SheaMDochertyAJThe N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity19913080978102Search in Google Scholar
Arza B, De Maeyer M, Félez J, Collen D, Lijnen HR. Critical role of glutamic acid 202 in the enzymatic activity of stromelysin-1 (MMP-3). Eur J Biochem. 2001; 268: 826–831.ArzaBDe MaeyerMFélezJCollenDLijnenHRCritical role of glutamic acid 202 in the enzymatic activity of stromelysin-1 (MMP-3)2001268826831Search in Google Scholar
Janowska-Wieczorek A, Marquez LA, Dobrowsky A, Ratajczak MZ, Cabuhat ML. Differential MMP and TIMP production by human marrow and peripheral blood CD34(+) cells in response to chemokines. Exp Hematol. 2000; 28: 1274–1285.Janowska-WieczorekAMarquezLADobrowskyARatajczakMZCabuhatMLDifferential MMP and TIMP production by human marrow and peripheral blood CD34(+) cells in response to chemokines20002812741285Search in Google Scholar
Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. BiochimBiophys Acta. 2000; 1477: 267–283.BrewKDinakarpandianDNagaseHTissue inhibitors of metalloproteinases: evolution, structure and function20001477267283Search in Google Scholar
Gasson JC, Golde DW, Kaufman SE, Westbrook CA, Hewick RM, Kaufman RJ, Wong GG, Temple PA, Leary AC, Brown EL, et al. Molecular characterization and expression of the gene encoding human erythroid-potentiating activity. Nature. 1985; 315: 768–771.GassonJCGoldeDWKaufmanSEWestbrookCAHewickRMKaufmanRJWongGGTemplePALearyACBrownELMolecular characterization and expression of the gene encoding human erythroid-potentiating activity1985315768771Search in Google Scholar
Lambert E, Dassé E, Haye B, Petitfrère E. TIMPs as multifacial proteins. Crit. Rev. Oncol Hematol. 2004; 49: 187–198.LambertEDasséEHayeBPetitfrèreETIMPs as multifacial proteins200449187198Search in Google Scholar
Ozenci V, Rinaldi L, Teleshova N, Matusevicius D, Kivisäkk P, Kouwenhoven M, Link H. Metalloproteinases and their tissue inhibitors in multiple sclerosis. J Autoimmun. 1999; 12: 297–303.OzenciVRinaldiLTeleshovaNMatuseviciusDKivisäkkPKouwenhovenMLinkHMetalloproteinases and their tissue inhibitors in multiple sclerosis199912297303Search in Google Scholar
Stetler-Stevenson WG, Bersch N, Golde DW. Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett. 1992; 296: 231–234.Stetler-StevensonWGBerschNGoldeDWTissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity1992296231234Search in Google Scholar
Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci. 1994; 107: 2373–2379.HayakawaTYamashitaKOhuchiEShinagawaACell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2)199410723732379Search in Google Scholar
Wang T, Yamashita K, Iwata K, Hayakawa T. Both tissue inhibitors of metalloproteinases-1 (TIMP-1) and TIMP-2 activate Ras but through different pathways. BiochemBiophys Res Commun. 2002; 296: 201–205.WangTYamashitaKIwataKHayakawaTBoth tissue inhibitors of metalloproteinases-1 (TIMP-1) and TIMP-2 activate Ras but through different pathways2002296201205Search in Google Scholar
Jotwani R, Eswaran SV, Moonga S, Cutler CW. MMP-9/TIMP-1 imbalance induced in human dendritic cells by Porphyromonasgingivalis. FEMS Immunol Med Microbiol. 2010; 58: 314–321.JotwaniREswaranSVMoongaSCutlerCWMMP-9/TIMP-1 imbalance induced in human dendritic cells by Porphyromonasgingivalis201058314321Search in Google Scholar
Kurzepa J, Szczepanska-Szerej A, Stryjecka-Zimmer M, Malecka-Massalska T, Stelmasiak Z. Simvastatin could prevent increase of the serum MMP-9/TIMP-1 ratio in acute ischaemic stroke. Folia Biol (Praha). 2006; 52: 181–183.KurzepaJSzczepanska-SzerejAStryjecka-ZimmerMMalecka-MassalskaTStelmasiakZSimvastatin could prevent increase of the serum MMP-9/TIMP-1 ratio in acute ischaemic stroke200652181183Search in Google Scholar
Reis ST, Pontes-Junior J, Antunes AA, de Sousa-Canavez JM, Dall’Oglio MF, Passerotti CC, Abe DK, Crippa A, da Cruz JA, Timoszczuk LM, et al. MMP-9 overexpression due to TIMP-1 and RECK underexpression is associated with prognosis in prostate cancer. Int J Biol Markers. 2011; 26: 255–261.ReisSTPontes-JuniorJAntunesAAde Sousa-CanavezJMDall’OglioMFPasserottiCCAbeDKCrippaAda CruzJATimoszczukLMMMP-9 overexpression due to TIMP-1 and RECK underexpression is associated with prognosis in prostate cancer201126255261Search in Google Scholar
Roy R, Morad G, Jedinak A, Moses MA. Metalloproteinases and their roles in human cancer. Anat Rec. 2020; 303: 1557–1572.RoyRMoradGJedinakAMosesMAMetalloproteinases and their roles in human cancer202030315571572Search in Google Scholar
Turunen SP, Tatti-Bugaeva O, Lehti K. Membrane-type matrix metalloproteases as diverse effectors of cancer progression. BiochimBiophys Acta Mol Cell Res. 2017; 1864: 1974–1988.TurunenSPTatti-BugaevaOLehtiKMembrane-type matrix metalloproteases as diverse effectors of cancer progression2017186419741988Search in Google Scholar
Noë V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci. 2001; 114: 111–118.NoëVFingletonBJacobsKCrawfordHCVermeulenSSteelantWBruyneelEMatrisianLMMareelMRelease of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-12001114111118Search in Google Scholar
Sakamoto T, Seiki M. A membrane protease regulates energy production in macrophages by activating hypoxia-inducible factor-1 via a non-proteolytic mechanism. J Biol Chem. 2010; 285: 29951–29964.SakamotoTSeikiMA membrane protease regulates energy production in macrophages by activating hypoxia-inducible factor-1 via a non-proteolytic mechanism20102852995129964Search in Google Scholar
Nowak E, Bednarek I. Epithelial to mesenchymal transition in carcinogenesis [Przejścieepitelialno-mezenchymalne w procesachnowotworzenia]. Post Biol Kom. 2018; 3: 223–236.NowakEBednarekIEpithelial to mesenchymal transition in carcinogenesis [Przejścieepitelialno-mezenchymalne w procesachnowotworzenia]20183223236Search in Google Scholar
Dudzik P, Trojan SE, Ostrowska B, Zemanek G, Dulińska-Litewka J, Laidler P, Kocemba-Pilarczyk KA. The epigenetic modifier 5-aza-2-deoxycytidine triggers the expression of CD146 gene in prostate cancer cells. Anticancer Res. 2019; 39: 2395–2403.DudzikPTrojanSEOstrowskaBZemanekGDulińska-LitewkaJLaidlerPKocemba-PilarczykKAThe epigenetic modifier 5-aza-2-deoxycytidine triggers the expression of CD146 gene in prostate cancer cells20193923952403Search in Google Scholar
Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol. 1997; 139: 1861–1872.LochterAGalosySMuschlerJFreedmanNWerbZBissellMJMatrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells199713918611872Search in Google Scholar
Leroyer AS, Blin MG, Bachelier R, Bardin N, Blot-Chabaud M, Dignat-George F. CD146 (Cluster of Differentiation 146). ArteriosclerThrombVasc Biol. 2019; 39: 1026–1033.LeroyerASBlinMGBachelierRBardinNBlot-ChabaudMDignat-GeorgeFCD146 (Cluster of Differentiation 146)20193910261033Search in Google Scholar
Liu C, Jiang S, Xie H, Jia H, Li R, Zhang K, Wang N, Lin P, Yu X. Long non-coding RNA AC245100.4 contributes to prostate cancer migration via regulating PAR2 and activating p38-MAPK pathway. Med Oncol. 2022; 39: 94.LiuCJiangSXieHJiaHLiRZhangKWangNLinPYuXLong non-coding RNA AC245100.4 contributes to prostate cancer migration via regulating PAR2 and activating p38-MAPK pathway20223994Search in Google Scholar
Han Z, Mo R, Cai S, Feng Y, Tang Z, Ye J, Liu R, Cai Z, Zhu X, Deng Y, et al. Differential expression of E2F transcription factors and their functional and prognostic roles in human prostate cancer. Front Cell Dev Biol. 2022; 10: 831329.HanZMoRCaiSFengYTangZYeJLiuRCaiZZhuXDengYDifferential expression of E2F transcription factors and their functional and prognostic roles in human prostate cancer202210831329Search in Google Scholar
Chen B, Li R, Hernandez SC, Hanna A, Su K, Shinde AV, Frangogiannis NG. Differential effects of Smad2 and Smad3 in regulation of macrophage phenotype and function in the infarcted myocardium. J Mol Cell Cardiol. 2022; 171: 1–15.ChenBLiRHernandezSCHannaASuKShindeAVFrangogiannisNGDifferential effects of Smad2 and Smad3 in regulation of macrophage phenotype and function in the infarcted myocardium2022171115Search in Google Scholar
Karmakar D, Maity J, Mondal P, Shyam Chowdhury P, Sikdar N, Karmakar P, Das C, Sengupta S. E2F5 promotes prostate cancer cell migration and invasion through regulation of TFPI2, MMP-2 and MMP-9. Carcinogenesis. 2020; 41: 1767–1780.KarmakarDMaityJMondalPShyam ChowdhuryPSikdarNKarmakarPDasCSenguptaSE2F5 promotes prostate cancer cell migration and invasion through regulation of TFPI2, MMP-2 and MMP-920204117671780Search in Google Scholar
Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, Syed N, Hatzimichael E, Briasoulis E, Merlano M, et al. Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol. 2013; 133: 1278–1285.Lo NigroCWangHMcHughALattanzioLMatinRHarwoodCSyedNHatzimichaelEBriasoulisEMerlanoMMethylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma201313312781285Search in Google Scholar
Khokha R, Murthy A, Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol. 2013; 13: 649–665.KhokhaRMurthyAWeissAMetalloproteinases and their natural inhibitors in inflammation and immunity201313649665Search in Google Scholar
Zhao L, Li C, Liu F, Zhao Y, Liu J, Hua Y, Liu J, Huang J, Ge C. A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway. Onco Targets Ther. 2017; 10: 2115–2126.ZhaoLLiCLiuFZhaoYLiuJHuaYLiuJHuangJGeCA blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway20171021152126Search in Google Scholar
Rydlova M, Holubec L Jr, Ludvikova M Jr, Kalfert D, Franekova J, Povysil C, Ludvikova M. Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res. 2008; 28: 1389–1397.RydlovaMHolubecLJrLudvikovaMJrKalfertDFranekovaJPovysilCLudvikovaMBiological activity and clinical implications of the matrix metalloproteinases20082813891397Search in Google Scholar
Vizoso FJ, González LO, Corte MD, Rodríguez JC, Vázquez J, Lamelas ML, Junquera S, Merino AM, García-Muñiz JL. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer. 2007; 96: 903–911.VizosoFJGonzálezLOCorteMDRodríguezJCVázquezJLamelasMLJunqueraSMerinoAMGarcía-MuñizJLStudy of matrix metalloproteinases and their inhibitors in breast cancer200796903911Search in Google Scholar
Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S, Mazzarino MC. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res. 2005; 33: 44–50.MorgiaGFalsaperlaMMalaponteGMadoniaMIndelicatoMTravaliSMazzarinoMCMatrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer2005334450Search in Google Scholar
Anteby EY, Greenfield C, Natanson-Yaron S, Goldman-Wohl D, Hamani Y, Khudyak V, Ariel I, Yagel S. Vascular endothelial growth factor, epidermal growth factor and fibroblast growth factor-4 and -10 stimulate trophoblast plasminogen activator system and metalloproteinase-9. Mol Hum Reprod. 2004; 10: 229–235.AntebyEYGreenfieldCNatanson-YaronSGoldman-WohlDHamaniYKhudyakVArielIYagelSVascular endothelial growth factor, epidermal growth factor and fibroblast growth factor-4 and -10 stimulate trophoblast plasminogen activator system and metalloproteinase-9200410229235Search in Google Scholar
Brauer PR. MMPs-role in cardiovascular development and disease. Front Biosci. 2006; 11: 447–478.BrauerPRMMPs-role in cardiovascular development and disease200611447478Search in Google Scholar
Greenlee KJ, Werb Z, Kheradmand F. Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev. 2007; 87: 69–98.GreenleeKJWerbZKheradmandFMatrix metalloproteinases in lung: multiple, multifarious, and multifaceted2007876998Search in Google Scholar
Lamoreaux WJ, Fitzgerald ME, Reiner A, Hasty KA, Charles ST. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res. 1998; 55: 29–42.LamoreauxWJFitzgeraldMEReinerAHastyKACharlesSTVascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro1998552942Search in Google Scholar
Ok Atılgan A, Özdemir BH, YılmazAkçay E, Tepeoğlu M, Börcek P, Dirim A. Association between focal adhesion kinase and matrix metalloproteinase-9 expression in prostate adenocarcinoma and their influence on the progression of prostatic adenocarcinoma. Ann DiagnPathol. 2020; 45: 151480.Ok AtılganAÖzdemirBHYılmazAkçayETepeoğluMBörcekPDirimAAssociation between focal adhesion kinase and matrix metalloproteinase-9 expression in prostate adenocarcinoma and their influence on the progression of prostatic adenocarcinoma202045151480Search in Google Scholar
Defilippi P, Di Stefano P, Cabodi S. p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol. 2006; 16: 257–263.DefilippiPDi StefanoPCabodiSp130Cas: a versatile scaffold in signaling networks200616257263Search in Google Scholar
Ramos JW. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol. 2008; 40: 2707–2719.RamosJWThe regulation of extracellular signal-regulated kinase (ERK) in mammalian cells20084027072719Search in Google Scholar
Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010; 11: 329–341.VanhaesebroeckBGuillermet-GuibertJGrauperaMBilangesBThe emerging mechanisms of isoform-specific PI3K signalling201011329341Search in Google Scholar
Kumar AA, Buckley BJ, Ranson M. The urokinase plasminogen activation system in pancreatic cancer: prospective diagnostic and therapeutic targets. Biomolecules. 2022; 12: 152.KumarAABuckleyBJRansonMThe urokinase plasminogen activation system in pancreatic cancer: prospective diagnostic and therapeutic targets202212152Search in Google Scholar
Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. ArteriosclerThrombVasc Biol. 2001; 21: 1104–1117.PepperMSRole of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis20012111041117Search in Google Scholar
Oblander SA, Zhou Z, Gálvez BG, Starcher B, Shannon JM, Durbeej M, Arroyo AG, Tryggvason K, Apte SS. Distinctive functions of membrane type 1 matrix-metalloprotease (MT1-MMP or MMP-14) in lung and submandibular gland development are independent of its role in pro-MMP-2 activation. Dev Biol. 2005; 277: 255–269.OblanderSAZhouZGálvezBGStarcherBShannonJMDurbeejMArroyoAGTryggvasonKApteSSDistinctive functions of membrane type 1 matrix-metalloprotease (MT1-MMP or MMP-14) in lung and submandibular gland development are independent of its role in pro-MMP-2 activation2005277255269Search in Google Scholar
Kheradmand F, Rishi K, Werb Z. Signaling through the EGF receptor controls lung morphogenesis in part by regulating MT1-MMP-mediated activation of gelatinase A/MMP2. J Cell Sci. 2002; 115: 839–848.KheradmandFRishiKWerbZSignaling through the EGF receptor controls lung morphogenesis in part by regulating MT1-MMP-mediated activation of gelatinase A/MMP22002115839848Search in Google Scholar
Ganser GL, Stricklin GP, Matrisian LM. EGF and TGF alpha influence in vitro lung development by the induction of matrix-degrading metalloproteinases. Int J Dev Biol. 1991; 35: 453–461.GanserGLStricklinGPMatrisianLMEGF and TGF alpha influence in vitro lung development by the induction of matrix-degrading metalloproteinases199135453461Search in Google Scholar
Bahmad HF, Jalloul M, Azar J, Moubarak MM, Samad TA, Mukherji D, Al-Sayegh M, Abou-Kheir W. Tumor microenvironment in prostate cancer: toward identification of novel molecular biomarkers for diagnosis, prognosis, and therapy development. Front Genet. 2021; 12: 652747.BahmadHFJalloulMAzarJMoubarakMMSamadTAMukherjiDAl-SayeghMAbou-KheirWTumor microenvironment in prostate cancer: toward identification of novel molecular biomarkers for diagnosis, prognosis, and therapy development202112652747Search in Google Scholar
Ozden F, Saygin C, Uzunaslan D, Onal B, Durak H, Aki H. Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival. J Cancer Res Clin Oncol. 2013; 139: 1373–1382.OzdenFSayginCUzunaslanDOnalBDurakHAkiHExpression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival201313913731382Search in Google Scholar
Nonsrijun N, Mitchai J, Brown K, Leksomboon R, Tuamsuk P. Overexpression of matrix metalloproteinase 11 in Thai prostatic adenocarcinoma is associated with poor survival. Asian Pac J Cancer Prev. 2013; 14: 3331–3335.NonsrijunNMitchaiJBrownKLeksomboonRTuamsukPOverexpression of matrix metalloproteinase 11 in Thai prostatic adenocarcinoma is associated with poor survival20131433313335Search in Google Scholar
Reis ST, Viana NI, Iscaife A, Pontes-Junior J, Dip N, Antunes AA, Guimarães VR, Santana I, Nahas WC, Srougi M, et al. Loss of TIMP-1 immune expression and tumor recurrence in localized prostate cancer. Int Braz J Urol. 2015; 41: 1088–1095.ReisSTVianaNIIscaifeAPontes-JuniorJDipNAntunesAAGuimarãesVRSantanaINahasWCSrougiMLoss of TIMP-1 immune expression and tumor recurrence in localized prostate cancer20154110881095Search in Google Scholar
Baspinar S, Bircan S, Ciris M, Karahan N, Bozkurt KK. Expression of NGF, GDNF and MMP-9 in prostate carcinoma. Pathol Res Pract. 2017; 213: 483–489.BaspinarSBircanSCirisMKarahanNBozkurtKKExpression of NGF, GDNF and MMP-9 in prostate carcinoma2017213483489Search in Google Scholar
Szarvas T, Csizmarik A, Váradi M, Fazekas T, Hüttl A, Nyirády P, Hadaschik B, Grünwald V, Tschirdewahn S, Shariat SF, et al. The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy. Urol Oncol. 2021; 39: 296.e11–296.e19.SzarvasTCsizmarikAVáradiMFazekasTHüttlANyirádyPHadaschikBGrünwaldVTschirdewahnSShariatSFThe prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy202139296.e11296.e19Search in Google Scholar
Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. PharmacolTher. 1997; 75: 69–75.RasmussenHSMcCannPPMatrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat1997756975Search in Google Scholar
Rosenbaum E, Zahurak M, Sinibaldi V, Carducci MA, Pili R, Laufer M, DeWeese TL, Eisenberger MA. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial. Clin Cancer Res. 2005; 11: 4437–4443.RosenbaumEZahurakMSinibaldiVCarducciMAPiliRLauferMDeWeeseTLEisenbergerMAMarimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial20051144374443Search in Google Scholar
Liang M, Wang J, Wu C, Wu M, Hu J, Dai J, Ruan H, Xiong S, Dong C. Targeting matrix metalloproteinase MMP3 greatly enhances oncolytic virus mediated tumor therapy. Translational Oncology. 2021; 14: 101221.LiangMWangJWuCWuMHuJDaiJRuanHXiongSDongCTargeting matrix metalloproteinase MMP3 greatly enhances oncolytic virus mediated tumor therapy202114101221Search in Google Scholar
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015; 373: 2005–2014.SparanoJAGrayRJMakowerDFPritchardKIAlbainKSHayesDFGeyerCEJrDeesECPerezEAOlsonJAProspective validation of a 21-gene expression assay in breast cancer201537320052014Search in Google Scholar
Jackson HW, Defamie V, Waterhouse P, Khokha R. TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer. 2017; 17: 38–53.JacksonHWDefamieVWaterhousePKhokhaRTIMPs: versatile extracellular regulators in cancer2017173853Search in Google Scholar
Gobin E, Bagwell K, Wagner J, Mysona D, Sandirasegarane S, Smith N, Bai S, Sharma A, Schleifer R, She JX. A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential. BMC Cancer. 2019; 19: 581.GobinEBagwellKWagnerJMysonaDSandirasegaraneSSmithNBaiSSharmaASchleiferRSheJXA pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential201919581Search in Google Scholar
Levin M, Udi Y, Solomonov I, Sagi I. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects. BiochimBiophys Acta Mol Cell Res. 2017; 1864: 1927–1939.LevinMUdiYSolomonovISagiINext generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects2017186419271939Search in Google Scholar